Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat vs BAT in Relapsed/Refractory Myelofibrosis
NCT04576156Phase 3Active, not recruiting
- Sponsor
- Geron Corporation
- Start
- Apr 2021
- Primary completion
- Jun 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoint: Overall survival. Started Apr 2021; status: active, not recruiting.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04576156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576156.